{"id":454132,"date":"2021-03-09T16:04:23","date_gmt":"2021-03-09T21:04:23","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=454132"},"modified":"2021-03-09T16:04:23","modified_gmt":"2021-03-09T21:04:23","slug":"neurocrine-biosciences-to-present-at-the-oppenheimer-31st-annual-healthcare-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/neurocrine-biosciences-to-present-at-the-oppenheimer-31st-annual-healthcare-conference\/","title":{"rendered":"Neurocrine Biosciences to Present at the Oppenheimer 31st Annual Healthcare Conference"},"content":{"rendered":"
\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

\n SAN DIEGO<\/span>, March 9, 2021<\/span> \/PRNewswire\/ — Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the Oppenheimer 31st<\/sup> Annual Healthcare Conference at 4:30 p.m. Eastern Time on Tuesday<\/span> Mar. 16, 2021. Matt Abernethy<\/span>, Chief Financial Officer, will present at the conference.<\/p>\n

\n

\n
\n \"(PRNewsfoto\/Neurocrine
\n <\/a>\n <\/p>\n<\/p><\/div>\n

The live presentation will be webcast and may be accessed on the Company’s website under Investors at www.neurocrine.com<\/a>. A replay of the presentation will be available on the website approximately one hour after the conclusion of the events and will be archived for approximately one month.<\/p>\n

\n About Neurocrine Biosciences
<\/b>Neurocrine Biosciences is a neuroscience-focused, biopharmaceutical company dedicated to discovering, developing and delivering life-changing treatments for people with serious, challenging and under-addressed neurological, endocrine and psychiatric disorders. The company’s diverse portfolio includes FDA-approved treatments for tardive dyskinesia, Parkinson’s disease, endometriosis*, uterine fibroids* and clinical programs in multiple therapeutic areas. For nearly three decades, Neurocrine Biosciences has specialized in targeting and interrupting disease-causing mechanisms involving the interconnected pathways of the nervous and endocrine systems. For more information, visit\u00a0neurocrine.com<\/a>, and follow\u00a0the company on\u00a0LinkedIn<\/a>.\u00a0(*in collaboration with AbbVie)<\/i><\/p>\n

<\/div>\n

\n \"Cision\" View original content to download multimedia:http:\/\/www.prnewswire.com\/news-releases\/neurocrine-biosciences-to-present-at-the-oppenheimer-31st-annual-healthcare-conference-301243884.html<\/a><\/p>\n

SOURCE Neurocrine Biosciences, Inc.<\/p>\n<\/p><\/div>\n

\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

PR Newswire SAN DIEGO, March 9, 2021 \/PRNewswire\/ — Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the Oppenheimer 31st Annual Healthcare Conference at 4:30 p.m. Eastern Time on Tuesday Mar. 16, 2021. Matt Abernethy, Chief Financial Officer, will present at the conference. The live presentation will be webcast and may be accessed on the Company’s website under Investors at www.neurocrine.com. A replay of the presentation will be available on the website approximately one hour after the conclusion of the events and will be archived for approximately one month. About Neurocrine BiosciencesNeurocrine Biosciences is a neuroscience-focused, biopharmaceutical company dedicated to discovering, developing and delivering life-changing treatments for people with serious, challenging and under-addressed neurological, endocrine and psychiatric disorders. The company’s … <\/p>\n

Continue reading “Neurocrine Biosciences to Present at the Oppenheimer 31st Annual Healthcare Conference”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-454132","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nNeurocrine Biosciences to Present at the Oppenheimer 31st Annual Healthcare Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/neurocrine-biosciences-to-present-at-the-oppenheimer-31st-annual-healthcare-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Neurocrine Biosciences to Present at the Oppenheimer 31st Annual Healthcare Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire SAN DIEGO, March 9, 2021 \/PRNewswire\/ — Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the Oppenheimer 31st Annual Healthcare Conference at 4:30 p.m. Eastern Time on Tuesday Mar. 16, 2021. Matt Abernethy, Chief Financial Officer, will present at the conference. The live presentation will be webcast and may be accessed on the Company’s website under Investors at www.neurocrine.com. A replay of the presentation will be available on the website approximately one hour after the conclusion of the events and will be archived for approximately one month. About Neurocrine BiosciencesNeurocrine Biosciences is a neuroscience-focused, biopharmaceutical company dedicated to discovering, developing and delivering life-changing treatments for people with serious, challenging and under-addressed neurological, endocrine and psychiatric disorders. The company’s … Continue reading "Neurocrine Biosciences to Present at the Oppenheimer 31st Annual Healthcare Conference"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/neurocrine-biosciences-to-present-at-the-oppenheimer-31st-annual-healthcare-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-03-09T21:04:23+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnewswire.com\/media\/678850\/Neurocrine_Biosciences_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neurocrine-biosciences-to-present-at-the-oppenheimer-31st-annual-healthcare-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neurocrine-biosciences-to-present-at-the-oppenheimer-31st-annual-healthcare-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Neurocrine Biosciences to Present at the Oppenheimer 31st Annual Healthcare Conference\",\"datePublished\":\"2021-03-09T21:04:23+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neurocrine-biosciences-to-present-at-the-oppenheimer-31st-annual-healthcare-conference\\\/\"},\"wordCount\":208,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neurocrine-biosciences-to-present-at-the-oppenheimer-31st-annual-healthcare-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/678850\\\/Neurocrine_Biosciences_Logo.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neurocrine-biosciences-to-present-at-the-oppenheimer-31st-annual-healthcare-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neurocrine-biosciences-to-present-at-the-oppenheimer-31st-annual-healthcare-conference\\\/\",\"name\":\"Neurocrine Biosciences to Present at the Oppenheimer 31st Annual Healthcare Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neurocrine-biosciences-to-present-at-the-oppenheimer-31st-annual-healthcare-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neurocrine-biosciences-to-present-at-the-oppenheimer-31st-annual-healthcare-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/678850\\\/Neurocrine_Biosciences_Logo.jpg\",\"datePublished\":\"2021-03-09T21:04:23+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neurocrine-biosciences-to-present-at-the-oppenheimer-31st-annual-healthcare-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neurocrine-biosciences-to-present-at-the-oppenheimer-31st-annual-healthcare-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neurocrine-biosciences-to-present-at-the-oppenheimer-31st-annual-healthcare-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/678850\\\/Neurocrine_Biosciences_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/678850\\\/Neurocrine_Biosciences_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neurocrine-biosciences-to-present-at-the-oppenheimer-31st-annual-healthcare-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Neurocrine Biosciences to Present at the Oppenheimer 31st Annual Healthcare Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Neurocrine Biosciences to Present at the Oppenheimer 31st Annual Healthcare Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/neurocrine-biosciences-to-present-at-the-oppenheimer-31st-annual-healthcare-conference\/","og_locale":"en_US","og_type":"article","og_title":"Neurocrine Biosciences to Present at the Oppenheimer 31st Annual Healthcare Conference - Market Newsdesk","og_description":"PR Newswire SAN DIEGO, March 9, 2021 \/PRNewswire\/ — Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the Oppenheimer 31st Annual Healthcare Conference at 4:30 p.m. Eastern Time on Tuesday Mar. 16, 2021. Matt Abernethy, Chief Financial Officer, will present at the conference. The live presentation will be webcast and may be accessed on the Company’s website under Investors at www.neurocrine.com. A replay of the presentation will be available on the website approximately one hour after the conclusion of the events and will be archived for approximately one month. About Neurocrine BiosciencesNeurocrine Biosciences is a neuroscience-focused, biopharmaceutical company dedicated to discovering, developing and delivering life-changing treatments for people with serious, challenging and under-addressed neurological, endocrine and psychiatric disorders. The company’s … Continue reading \"Neurocrine Biosciences to Present at the Oppenheimer 31st Annual Healthcare Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/neurocrine-biosciences-to-present-at-the-oppenheimer-31st-annual-healthcare-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2021-03-09T21:04:23+00:00","og_image":[{"url":"https:\/\/mma.prnewswire.com\/media\/678850\/Neurocrine_Biosciences_Logo.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neurocrine-biosciences-to-present-at-the-oppenheimer-31st-annual-healthcare-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neurocrine-biosciences-to-present-at-the-oppenheimer-31st-annual-healthcare-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Neurocrine Biosciences to Present at the Oppenheimer 31st Annual Healthcare Conference","datePublished":"2021-03-09T21:04:23+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neurocrine-biosciences-to-present-at-the-oppenheimer-31st-annual-healthcare-conference\/"},"wordCount":208,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neurocrine-biosciences-to-present-at-the-oppenheimer-31st-annual-healthcare-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/678850\/Neurocrine_Biosciences_Logo.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neurocrine-biosciences-to-present-at-the-oppenheimer-31st-annual-healthcare-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/neurocrine-biosciences-to-present-at-the-oppenheimer-31st-annual-healthcare-conference\/","name":"Neurocrine Biosciences to Present at the Oppenheimer 31st Annual Healthcare Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neurocrine-biosciences-to-present-at-the-oppenheimer-31st-annual-healthcare-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neurocrine-biosciences-to-present-at-the-oppenheimer-31st-annual-healthcare-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/678850\/Neurocrine_Biosciences_Logo.jpg","datePublished":"2021-03-09T21:04:23+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neurocrine-biosciences-to-present-at-the-oppenheimer-31st-annual-healthcare-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/neurocrine-biosciences-to-present-at-the-oppenheimer-31st-annual-healthcare-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neurocrine-biosciences-to-present-at-the-oppenheimer-31st-annual-healthcare-conference\/#primaryimage","url":"https:\/\/mma.prnewswire.com\/media\/678850\/Neurocrine_Biosciences_Logo.jpg","contentUrl":"https:\/\/mma.prnewswire.com\/media\/678850\/Neurocrine_Biosciences_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neurocrine-biosciences-to-present-at-the-oppenheimer-31st-annual-healthcare-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Neurocrine Biosciences to Present at the Oppenheimer 31st Annual Healthcare Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/454132","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=454132"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/454132\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=454132"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=454132"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=454132"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}